Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19513096 | 0.87 | ESR2 (0.55) | ESR2NR1H2JAK2JAK1KCNJ1 | |
| SCHEMBL20945425 | 0.86 | KCNJ1 (0.47) | KCNJ1NPC1RAB9AS1PR1MEN1 | |
| SCHEMBL1948364 | 0.81 | ESR2 (0.60) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL1948827 | 0.81 | ESR2 (0.60) | ESR2NR1H2JAK2NPC1RAB9A | |
| SCHEMBL17797522 | 0.81 | ESR2 (0.56) | ESR2NR1H2JAK2NPC1RAB9A | |
| SCHEMBL31413054 | 0.80 | ESR2 (0.56) | ESR2NR1H2JAK2JAK1GPR119 | |
| SCHEMBL30474184 | 0.80 | ESR2 (0.56) | ESR2NR1H2JAK2JAK1GPR119 | |
| SCHEMBL5599594 | 0.76 | ESR2 (0.62) | ESR2NR1H2GPR119RAB9AMEN1 | |
| SCHEMBL25074088 | 0.76 | ESR2 (0.61) | ESR2NR1H2JAK2GPR119NPC1 | |
| SCHEMBL29098008 | 0.76 | NR1H2 (0.52) | ESR2NR1H2JAK2GPR119NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184662-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | NR0B1, GRK4, CRKL | ESR2 808/4885NR1H2 32/4885JAK2 1467/4885 |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | NR0B1, GRK4, CRKL | ESR2 808/4885NR1H2 32/4885JAK2 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.